Abstract 5749
Background
Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age.
Methods
We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered.
Results
170 pts were included: 61.76% male, 38.24% female. The median age at the diagnosis was 58.83. Regarding the site of origin, the most frequent was gastro-intestinal system (54.71%), followed by pancreas (27.06%) and lung (8.24%). G1 NENs were 54.11%, G2 42.94% and typical lung carcinoid 2.95%; 31.76% were affected by a carcinoid syndrome or clinical conditions such as gastrinoma, insulinoma and Zollinger-Ellison. The median PFS was 20.18 months. Side effects (SEs) were registered in 25 pts (14.71%), the most frequent were cholecystitis (4%), G1 asthenia (12%), G1 hyperglycemia (8%), G1 steatorrhea (76%). We divided patients in 4 groups considering the age at the diagnosis: lower than 60 years, 61-70, 71-80 and more than 81 years. With the increase of age there was a higher percentage of SEs (Tab.1) with a maximum percentage of 20.41% in the group with an age of 71-80 years. The treatment was well tolerated without life-threatening side effects also in the group of patients with an age > 70 years. Tab. 1Table: 520P
Age at the diagnosis (years) | % side effects |
---|---|
<60 | 10,00% |
61-70 | 13,73% |
71-80 | 20,41% |
>81 | 20,00% |
Conclusions
We concluded that in this setting of patients, with an age >70 and a WD NEN in progression to standard doses of SSA, HD-SSA represents a safe and effective second line therapy with a median PFS of 20.80 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3266 - Morphology of tumor-associated macrophages dictates the prognosis of patients with colorectal liver metastases.
Presenter: Matteo Donadon
Session: Poster Display session 2
Resources:
Abstract
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract